Literature DB >> 24673583

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia.

Naomi E van der Sligte1, Manuela Krumbholz, Agata Pastorczak, Blanca Scheijen, Josephine T Tauer, Christina Nowasz, Edwin Sonneveld, Geertruida H de Bock, Tiny G J Meeuwsen-de Boer, Simon van Reijmersdal, Roland P Kuiper, Jutta Bradtke, Markus Metzler, Meinolf Suttorp, Evelina S J M de Bont, Frank N van Leeuwen.   

Abstract

Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  IKZF1; copy number alterations; lymphoid blast crisis; paediatric CML

Mesh:

Substances:

Year:  2014        PMID: 24673583     DOI: 10.1111/bjh.12850

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update.

Authors:  Heyang Zhang; Meng Liu; Xiaoxue Wang; Yuan Ren; Young Mi Kim; Xianfu Wang; Xianglan Lu; Hui Pang; Guangming Liu; Yue Gu; Mingran Sun; Yunpeng Shi; Chuan Zhang; Yaowen Zhang; Jianqin Zhang; Shibo Li; Lijun Zhang
Journal:  Front Genet       Date:  2021-08-10       Impact factor: 4.599

2.  Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Jonathon L Payne; Chunhua Song; Yali Ding; Pavan Kumar Dhanyamraju; Yevgeniya Bamme; Joseph W Schramm; Dhimant Desai; Arati Sharma; Chandrika Gowda; Sinisa Dovat
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

Review 3.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

4.  Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.

Authors:  Neetu Singh; Anil Kumar Tripathi; Dinesh Kumar Sahu; Archana Mishra; Margaret Linan; Bianca Argente; Julia Varkey; Niranjan Parida; Rebecca Chowdhry; Hari Shyam; Nawazish Alam; Shivani Dixit; Pratap Shankar; Abhishek Mishra; Avinash Agarwal; Chris Yoo; Madan Lal Brahma Bhatt; Ravi Kant
Journal:  Oncotarget       Date:  2018-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.